Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the prevalence of cirrhotic cardiomyopathy in patients with cirrhosis, and to analyze the correlation between the severity of cirrhosis and cardiac dysfunction. To investigate the risk factors for cirrhotic cardiomyopathy, and raise clinicians' awareness of cirrhotic cardiomyopathy, early assessment and intervention to improve long-term outcomes in patients with cirrhosis.
Liver cirrhosis is the terminal stage of the development of chronic liver disease caused by various reasons, and it is often accompanied by multiple complications. Late cirrhosis is often accompanied by obvious changes in liver and systemic hemodynamics. Patients with liver cirrhosis are in a highly dynamic cycle Status: lower arterial blood pressure, increased heart rate, increased cardiac output, peripheral vascular resistance, which often lead to changes in myocardial structure and function, called cirrhotic cardiomyopathy. Cirrhotic cardiomyopathy (CCM) is defined as cardiac dysfunction in patients with end-stage liver disease in the absence of prior heart disease. The true burden of CCM among patients with ESLD is currently unknown. Prior studies evaluated CCM prevalence and estimated it to be approximately 50%, however, this estimate was based on the old criteria. In 2020, the Cirrhotic Cardiomyopathy Association updated the diagnostic criteria for cirrhotic cardiomyopathy. At present, the true prevalence of cirrhotic cardiomyopathy still needs to be reassessed. In addition, studies on the risk factors for cirrhotic cardiomyopathy are rare. Based on the above research background, carry out this research.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patients with liver cirrhosis | cirrhosis based on either clinical/radiological parameters or liver histology |
| |
| control group | Healthy ubjects without known heart disease |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Not | Other | Not |
|
| Measure | Description | Time Frame |
|---|---|---|
| cirrhotic cardiomyopathy | Different levels of left ventricular diastolic dysfunction in patients with liver cirrhosis | Within 48 hours after hospitalization |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| N-terminal Pro-brain Natriuretic Peptide serum level | Venous blood sampling was performed in the morning, after a 12-h fast. serum levels of NT-proBNP were measured by an electrochemiluminescence immunoassay. | Within 48 hours after hospitalization |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
From December 1, 2020 to December 31, 2021, The clear diagnosis of cirrhosis in patients caused by various reasons who have come to our hospital for digestive medicine.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| YanJing Gao, PhD.MD | Qilu Hospital of Shandong University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Qilu Hospital , Shandong University | Jinan | Shandong | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38407871 | Derived | Xu H, Zhang Y, Gao Y. Prevalence and risk factors for cirrhotic cardiomyopathy: a prospective cross-sectional study. Eur J Gastroenterol Hepatol. 2024 Apr 1;36(4):469-475. doi: 10.1097/MEG.0000000000002716. Epub 2024 Feb 16. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008103 | Liver Cirrhosis |
| D005355 | Fibrosis |
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D057126 | Nuclear Receptor Subfamily 4, Group A, Member 2 |
| ID | Term |
|---|---|
| D057093 | Orphan Nuclear Receptors |
| D004268 | DNA-Binding Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided
Not provided
Not provided
Not provided
| D018160 | Receptors, Cytoplasmic and Nuclear |